# Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis

> **NCT05590455** · PHASE2 · RECRUITING · sponsor: **ANRS, Emerging Infectious Diseases** · enrollment: 130 (estimated)

## Conditions studied

- Tuberculous Meningitis
- HIV I Infection

## Interventions

- **DRUG:** Adalimumab Injection

## Key facts

- **NCT ID:** NCT05590455
- **Lead sponsor:** ANRS, Emerging Infectious Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-11
- **Primary completion:** 2027-06
- **Final completion:** 2027-12
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05590455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05590455, "Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05590455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*